Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.

Khan AA, Lambert LH Jr, Remington JS, Araujo FG.

Antimicrob Agents Chemother. 1999 Apr;43(4):758-62.

3.

Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine.

Ferreira RA, Oliveira AB, Ribeiro MF, Tafuri WL, Vitor RW.

Exp Parasitol. 2006 Jun;113(2):125-9. Epub 2006 Feb 3.

PMID:
16458300
4.

Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.

Barbosa BF, Gomes AO, Ferro EA, Napolitano DR, Mineo JR, Silva NM.

Vet Parasitol. 2012 Jun 8;187(1-2):44-52. doi: 10.1016/j.vetpar.2011.12.039. Epub 2012 Jan 10.

PMID:
22281151
5.

Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.

Martins-Duarte ÉS, de Souza W, Vommaro RC.

Exp Parasitol. 2013 Mar;133(3):294-9. doi: 10.1016/j.exppara.2012.12.011. Epub 2012 Dec 25.

7.

Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo.

de Oliveira TC, Silva DA, Rostkowska C, Béla SR, Ferro EA, Magalhães PM, Mineo JR.

Exp Parasitol. 2009 Jul;122(3):233-41. doi: 10.1016/j.exppara.2009.04.010. Epub 2009 Apr 21.

PMID:
19389400
8.

In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.

Romand S, Della Bruna C, Farinotti R, Derouin F.

Antimicrob Agents Chemother. 1996 Sep;40(9):2015-20.

9.

Ketolide ABT-773 is active against Toxoplasma gondii.

Khan AA, Araujo FG, Craft JC, Remington JS.

J Antimicrob Chemother. 2000 Sep;46(3):489-92.

PMID:
10980181
10.

Two 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against Toxoplasma gondii.

Khan AA, Nasr M, Araujo FG.

Antimicrob Agents Chemother. 1998 Sep;42(9):2284-9.

11.

In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.

Romand S, Bryskier A, Moutot M, Derouin F.

J Antimicrob Chemother. 1995 Jun;35(6):821-32.

PMID:
7559193
13.

Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.

Silva LA, Reis-Cunha JL, Bartholomeu DC, Vítor RW.

PLoS One. 2017 Jan 24;12(1):e0170689. doi: 10.1371/journal.pone.0170689. eCollection 2017.

14.
16.

The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.

Araujo FG, Khan AA, Slifer TL, Bryskier A, Remington JS.

Antimicrob Agents Chemother. 1997 Oct;41(10):2137-40.

17.

Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.

Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, Khan IA, Wadsworth S, Siekierka J, Curiel TJ.

Antimicrob Agents Chemother. 2007 Dec;51(12):4324-8. Epub 2007 Oct 8.

18.

The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.

Jost C, Reiter-Owona I, Liesenfeld O.

Parasitol Res. 2007 Nov;101(6):1603-9. Epub 2007 Sep 12.

PMID:
17846793
19.

Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice.

Lindsay DS, Kaur T, Mitchell SM, Goodwin DG, Strobl J, Dubey JP.

J Parasitol. 2005 Dec;91(6):1488-90.

PMID:
16544426
20.

Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis.

Andrade RM, Chaparro JD, Capparelli E, Reed SL.

PLoS Negl Trop Dis. 2014 Jul 31;8(7):e2973. doi: 10.1371/journal.pntd.0002973. eCollection 2014.

Supplemental Content

Support Center